ARMP Stock Overview
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Armata Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.55 |
| 52 Week High | US$5.26 |
| 52 Week Low | US$1.07 |
| Beta | 0.70 |
| 1 Month Change | -32.54% |
| 3 Month Change | -34.62% |
| 1 Year Change | 57.50% |
| 3 Year Change | -38.85% |
| 5 Year Change | n/a |
| Change since IPO | -45.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARMP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.0% | -4.2% | -3.7% |
| 1Y | 57.5% | -2.0% | 20.5% |
Return vs Industry: ARMP exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: ARMP exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| ARMP volatility | |
|---|---|
| ARMP Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARMP's share price has been volatile over the past 3 months.
Volatility Over Time: ARMP's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 66 | Deborah Birx | www.armatapharma.com |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Armata Pharmaceuticals, Inc. Fundamentals Summary
| ARMP fundamental statistics | |
|---|---|
| Market cap | US$92.18m |
| Earnings (TTM) | -US$69.04m |
| Revenue (TTM) | US$4.53m |
20.4x
P/S Ratio-1.3x
P/E RatioIs ARMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARMP income statement (TTM) | |
|---|---|
| Revenue | US$4.53m |
| Cost of Revenue | US$33.77m |
| Gross Profit | -US$29.24m |
| Other Expenses | US$39.80m |
| Earnings | -US$69.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.91 |
| Gross Margin | -645.64% |
| Net Profit Margin | -1,524.51% |
| Debt/Equity Ratio | -256.7% |
How did ARMP perform over the long term?
See historical performance and comparison